US 12,448,463 B2
Antibodies for botulinum neurotoxins
James D. Marks, Kensington, CA (US); and Maria Consuelo Garcia Rodriguez, San Francisco, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Dec. 3, 2021, as Appl. No. 17/541,837.
Application 15/870,635 is a division of application No. 14/966,959, filed on Dec. 11, 2015, granted, now 9,902,781, issued on Feb. 27, 2018.
Application 17/541,837 is a continuation of application No. 16/813,161, filed on Mar. 9, 2020, granted, now 11,225,525.
Application 16/813,161 is a continuation of application No. 15/870,635, filed on Jan. 12, 2018, granted, now 10,618,972, issued on Apr. 14, 2020.
Application 14/966,959 is a continuation of application No. 13/813,623, granted, now 9,243,057, issued on Jan. 26, 2016, previously published as PCT/US2011/050050, filed on Aug. 31, 2011.
Claims priority of provisional application 61/430,084, filed on Jan. 5, 2011.
Claims priority of provisional application 61/378,862, filed on Aug. 31, 2010.
Prior Publication US 2022/0089784 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/40 (2006.01); A61K 39/00 (2006.01); C07K 16/12 (2006.01); G01N 33/569 (2006.01); G01N 33/573 (2006.01)
CPC C07K 16/40 (2013.01) [C07K 16/1282 (2013.01); G01N 33/56911 (2013.01); G01N 33/573 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/20 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/33 (2013.01); G01N 2333/952 (2013.01)] 24 Claims
OG exemplary drawing
 
1. A composition comprising:
a) a first isolated nucleic acid comprising a nucleotide sequence encoding a variable heavy chain (VH) polypeptide comprising:
a VH CDR1 comprising the amino acid sequence of NYPMS (SEQ ID NO: 509),
a VH CDR2 comprising the amino acid sequence of SLTASGDNTFYADSVKG (SEQ ID NO: 510),
a VH CDR3 comprising the amino acid sequence of ALVGRYDISTGYYRPVMDS (SEQ ID NO: 511); and
b) a second isolated nucleic acid comprising a nucleotide sequence encoding a variable light chain (VL) polypeptide comprising:
a VL CDR1 comprising the amino acid sequence of RASQSVSSSYLA (SEQ ID NO: 512),
a VL CDR2 comprising the amino acid sequence of GTSSRAT (SEQ ID NO: 513), and
a VL CDR3 comprising the amino acid sequence of QQYNNWPLT (SEQ ID NO 514).